Nalaganje...
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia
Tyrosine kinase inhibitors (TKIs) directed against the ABL kinase are now used routinely during frontline therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and result in hematologic remission rates exceeding 90%. Minimal residual disease levels are generally lower wh...
Shranjeno v:
| izdano v: | Leukemia Suppl |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4851212/ https://ncbi.nlm.nih.gov/pubmed/27175253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leusup.2012.7 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|